UV Innovators closes Series A Funding

Seasoned medical and technology experts join forces to fill gap in UV surface disinfection solutions.

March 15, 2020 – Research Triangle, North Carolina -- UV Innovators, LLC, an ultraviolet technology company, successfully closed its Series A funding today from a North Carolina family investment office. UV Innovators’ executive team is a triumvirate of leaders in the technology, medical device, and science industry.  Todd M. Pope, chairman, has extensive experience in healthcare product commercialization s in public and private companies.  Named by Time magazine  as one of the 50 most influential people in healthcare in 2018, Mr. Pope is looking forward to a better future. “Closing our initial investment sets us on the right path to build a world-class team that can develop illumination technology to make our environments safer,” stated Mr. Pope. 

Dr. Nicholas Medendorp, Jr., co-founder and CEO, states, “UV Innovators’ focus is to create a safer future through commercialization of technologies in the defense against contagious pathogens.”  Stephen Grenon joined UV Innovators as Chief Technology Officer after developing key projects as Head of R&D for Johnson & Johnson’s Dry Eye platform, following the acquisition of Tear Science in 2017. 

“Both Steve and Nick are medical and technology experts with more than 200 US patents combined.  They both have successfully commercialized medical and industrial products that solved customer problems and generated billions of dollars in revenue,” said Mr. Pope. “This perfect partnering of experience, knowledge and desire has created a culture to find solutions to break the cycle of infection at this critical time.”

With the rise of a novel coronavirus (Covid-19), UV Innovators has accelerated its technology development and commercialization efforts to aid in the support of society’s health and well-being through the creation of effective UV disinfection products.  The $40B per year impact of hospital acquired infections on the healthcare system is minor compared to the global impact of COVID-19.  “It is imperative that we leverage our high intensity UV to inactivate deadly pathogens, like SARS-CoV-2,” states Dr. Medendorp.  The use of proceeds of this investment will enable commercialization of their UV technology, independent 3rd party pathogen inactivation testing and rapidly deploying devices into the marketplace to aid in the safe return from quarantine.


About UV Innovators, LLC

UV Innovators, LLC uses its extensive illumination and medical device intellectual property to deliver disinfection solutions across a vast set of markets -- from private aviation and clinical care facilities, to healthy office buildings and schools.  UV Innovators is set to redefine the standard of surface disinfection with the commercialization of its portable UVC product, which delivers the effective germ deactivating power of disinfection towers with the speed and mobility of a handheld device. For more information, visit www.uvinnovators.com or contact us at info@uvinnovators.com.

Forward-looking Statements

Except for historical information, all the statements, expectations, and assumptions contained in this press release are forward-looking statements. Actual results might differ materially from those explicit or implicit in the forward-looking statements. Important factors that could cause actual results to differ materially to include risks associated with technology development process; reliance on key personnel; the early stage of our business; competition; and other risks described in other Company press releases and presentations. UV Innovators assumes no obligation and does not intend to update these forward-looking statements, except as required by law.


Media Contact

Kathleen Regan